Trial Profile
A retrospective study comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Mar 2018
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 16 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium